June 27, 2018June 27, 2018

Trovagene Begins Testing PCM-075 Plus Zytiga in Advanced Prostate Cancer Patients

News

Trovagene will soon begin patient recruitment for its Phase 2 clinical trial evaluating PCM-075 in combination with Zytiga (abiraterone acetate) and prednisone for the treatment of metastatic, castration-resistant prostate cancer (mCRPC). The ... Read more

October 20, 2017October 21, 2017

Trovagene’s PCM-075 Increases Zytiga’s Punch Against Prostate Cancer, Studies Show

News

Trovagene’s enzyme inhibitor PCM-075 increases the punch of the prostate cancer therapy Zytiga (abiraterone), preclinical-trial studies show. PCM-075 is a selective polo-like kinase 1 (PLK1) inhibitor. It inhibits a protein called PLK1, whose levels ... Read more